Apremilast vs placebo for severe recurrent mouth ulcers
Treatments studied
Part of Mouth & dental clinical trials.
This Phase 3 trial tests whether apremilast can reduce severe, recurring mouth ulcers compared with an inactive placebo. It aims to improve ulcer frequency and pain while carefully checking safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older and have severe recurrent mouth ulcers that don’t respond to colchicine or you can’t tolerate it
- You’ve had these severe ulcer symptoms for at least 3 months (on colchicine 1 mg/day or more) or you’re intolerant to colchicine
- You have at least one mouth ulcer on the day you join the study
- You can understand and sign the consent form and follow study visits and instructions
- For people who could become pregnant: you’ll use abstinence or two reliable birth-control methods during the study
- You generally don’t have other mouth diseases or major uncontrolled medical problems that could explain the ulcers
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests apremilast to treat active juvenile psoriatic arthritis (joint inflammation) in children and teens. You may be able to join if your child’s condition is active despite prior treatments or if they couldn’t tolerate them.
This trial studies whether apremilast can help reduce mouth ulcers in children who have Behçet’s disease or juvenile psoriatic arthritis. You may be considered if your child finished a main study and is under 18, and can safely continue treatment.
This study tests apremilast to help reduce active, recurring mouth (oral) ulcers in children with Behçet’s disease. It may help if your child has had repeated mouth ulcers despite at least one non-biologic treatment.
This study tests whether apremilast (a pill) safely and effectively treats moderate-to-severe psoriasis. If you join, you will receive the medication and be monitored by the study team to see how well it works for you.
This study tests if ustekinumab or apremilast can help control Behçet's disease symptoms like mouth and genital ulcers, skin sores, and joint pain. It may be an option if standard treatments haven't worked well.
This trial tests whether adding apremilast, a medicine that reduces inflammation, helps people with chronic hives when antihistamines alone aren't enough. It may offer a new option for those who can't use other standard treatments like omalizumab or cyclosporine.
Hear when a new Recurrent Aphtous Stomatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.